Working... Menu

A Trial to Evaluate the Efficacy of Poziotinib, Pan HER Inhibitor in Recurrent/Metastatic Esophageal Cancer (R/M ESCC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03770988
Recruitment Status : Not yet recruiting
First Posted : December 10, 2018
Last Update Posted : February 22, 2019
Information provided by (Responsible Party):
Yonsei University

Brief Summary:

Esophageal cancer is the sixth most common cause of cancer deaths worldwide. Esophageal adenocarcinoma has become more common in Western countries. In many Asian countries, however, Esophageal Squamous Cell Carcinoma (ESCC) represents the most common esophageal cancer. In palliative chemotherapy for metastatic or recurrent ESCC, A combination of 5-fluorouracil and platinum was prescribed as a standard treatment for about 20 years. With this traditional regimen, the median progression free survival is approximately 7 months, and 1-year survival rate is reported to be 34%. Combinations of taxane and anthracycline are also considerable, but also shows the median survival less than one year. Though cytotoxic chemotherapy is current main treatment option, molecularly targeted agents are recently incorporated to improve survival in ESCC. There is a strong rationale for investigation of biologic agents targeting Epithelial Growth Factor Receptor (EGFR) family in ESCC. EGFR is frequently overexpressed in esophageal cancer and is known to be associated with poor prognosis. Several EGFR tyrosine kinase inhibitors (TKIs) have been studied in esophageal cancer subjects and have shown clinical effects. In a recent Phase II trial using dacomitinib, pan-human epidermal growth receptor TKI, Partial response was observed in 10 of the 49 esophageal cancer subjects, with a response rate of 20.8%.

Based on notable rationale in exploring impact of EGFR inhibition, we suggest multicenter phase II study to determine antitumor activity and safety of a other potent pan-HER inhibitor, Poziotinib in Esophageal Squamous cell carcinoma.

Condition or disease Intervention/treatment Phase
Inoperable or Recurrent or Metastatic Esophageal Squamous Carcinoma Drug: Treatment with Poziotinib Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 49 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single Arm Phase II Trial to Evaluate the Efficacy of Poziotinib, Pan HER Inhibitor in Recurrent/Metastatic Esophageal Cancer (R/M ESCC)
Estimated Study Start Date : April 1, 2019
Estimated Primary Completion Date : August 31, 2020
Estimated Study Completion Date : August 31, 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: poziotinib single arm study
Single Arm study
Drug: Treatment with Poziotinib
Treatment with Poziotinib

Primary Outcome Measures :
  1. Objective Response Rate [ Time Frame: every 8 weeks, assessed up to 100 weeks ]
    Objective Response Rate using RECIST 1.1

Secondary Outcome Measures :
  1. Overall Survival [ Time Frame: From date of randomization until date of death from any cause, whichever came first, assessed up to 100 months ]
  2. Progression Free Survival [ Time Frame: From date of randomization until date of death from any cause, whichever came first, assessed up to 100 months ]
  3. Duration of Response [ Time Frame: From date of randomization until date of death from any cause, whichever came first, assessed up to 100 months ]
  4. Safety assessed by incidence of treatment-emergent adverse events [ Time Frame: up to 100 weeks ]
    To evaluate the safety of Poziotinib, pan HER inhibitor in recurrent/metastatic esophageal cancer

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Histologically confirmed esophageal squamous cell carcinoma (Includes cases with pathologic findings with clinical course comparable to squamous cell carcinoma. For example, undifferentiated carcinoma)
  2. Diseases that can not achieve curative aim with radical surgery, radiation, or chemo-radiotherapy. Previous palliative chemotherapy including platinum-based agents for advanced or recurrent esophageal squamous cell carcinoma (If the disease progresses within 6 months after the curative platinum-based chemotherapy or disease progresses within 6 months after last adjuvant chemotherapy, it is considered to be the previous palliative chemotherapy.
  3. Have measurable disease based on RECIST 1.1.
  4. Be 20 years of age on day of signing informed consent.
  5. Performance status of 0 or 1 on the Eastern Cooperative Oncology Group Performance Scale.
  6. Demonstrate adequate organ function
  7. Absolute Neutrophil Count ≥ 1500/μL
  8. Platelet Count ≥100,000/μL
  9. Hemoglobin ≥ 9.0 g/dL
  10. Serum creatinine ≤
  11. Serum bilirubin ≤ 1.5 x ULN
  12. AST, ALT ≤ 1.5 x ULN (with liver metastasis ≤ 5.0 x ULN)
  13. Be willing and able to provide written informed consent/assent for the trial.

Exclusion Criteria:

  1. Without measurable lesion based on RECIST 1.1
  2. Has received prior therapy with EGFR/HER2 directed therapy.
  3. Has history of intestinal obstruction or recent bleeding (subjects with clinically significant hemorrhagic or clotting events within the past 6 months)
  4. Pregnant or lactating women
  5. Women who have not received a baseline pregnancy test or have a positive result. (A woman who has not undergone a previous hysterectomy, or history of amenorrhea of more than 12 months, or undergone bilateral oophorectomy is considered to be a non-pregnant menopausal woman.)
  6. Male or reproductive women who are not willing to use contraception during the trial
  7. Has a known additional malignancy that is progressing or requires active treatment within 3 years. (Except skin basal cell carcinoma, cervix epithelial carcinoma in situ, Superficial bladder cancer)
  8. Subjective who is likely to interfere with the understanding of the written consent or influence the compliance of the trial medication. Patients with a history of uncontrolled seizures, central nervous system disorders or psychiatric disorders that are considered clinically significant by the investigator
  9. Has stable LVEF of less than 50%
  10. Received organ transplants that require immunosuppressive therapy
  11. Has un-controlled active infectious disease.
  12. Has symptomatic central nerve system metastasis (Except in case of discontinuation of corticosteroids at least 2 weeks before clinical trials and radiologic and neurologically stable cases over 4 weeks)
  13. Has known history of, or any evidence of active, non-infectious pneumonitis.
  14. Has New York Heart Association, NYHA class III or IV Heart failure, un-controlled hypertension
  15. Experienced unstable angina or myocardial infarction within the last 6 months
  16. Has un-controlled arrhythmia or judged to have clinically significant cardiovascular abnormalities by investigators
  17. Incapability of Oral ingestion and digestion.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03770988

Layout table for location contacts
Contact: Hye Ryun Kim, MD 82 2 2228 8125

Layout table for location information
Korea, Republic of
Severance Hospital Not yet recruiting
Seoul, Korea, Republic of, 03722
Contact: Hye Ryun Kim, MD    82 2 2228 8125   
Sponsors and Collaborators
Yonsei University

Layout table for additonal information
Responsible Party: Yonsei University Identifier: NCT03770988     History of Changes
Other Study ID Numbers: 4-2017-1193
First Posted: December 10, 2018    Key Record Dates
Last Update Posted: February 22, 2019
Last Verified: February 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Yonsei University:
esophageal squamous carcinoma
pan-HER inhibitor

Additional relevant MeSH terms:
Layout table for MeSH terms
Esophageal Neoplasms
Carcinoma, Squamous Cell
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Head and Neck Neoplasms
Digestive System Diseases
Esophageal Diseases
Gastrointestinal Diseases
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Squamous Cell